


Managing Cirrhosis and Its Complications: Inpatient Strategies for Optimal Care

Jasmohan S. Bajaj, MD, MS, FACG

Division of Gastroenterology, Hepatology, and Nutrition,
Virginia Commonwealth University and Richmond VAMC,
Richmond, Virginia



Outline

- Why is it important to know about cirrhosis and complications?
- Management of cirrhosis-related complications (Package deal)
 - Hepatic encephalopathy, variceal bleeding, ascites, HRS-AKI
- Management of infections
 - SBP, other infections, consideration for MDROs and SBP prophylaxis
- Access and early consideration for liver transplant
- Diagnostic dilemmas related to cirrhosis
 - Missing a diagnosis of cirrhosis
 - Conflating ACLF with ALF
- Ensuring good outcomes at the time of discharge

Importance of cirrhosis

- Increasing in prevalence worldwide due to the obesity and alcohol pandemic with residual viral hepatitis.
- Long asymptomatic phase where it is often undiagnosed; diagnosis then requires a decompensating event or HCC.
- Greater burden from a clinical, and financial perspective compared to other chronic diseases.
- Very rapid progression from missed infection to acute on chronic liver failure and death if not acted upon.
- Needs early engagement with liver transplant teams and referral centers if not available in your center.

Obradović et al Hepatology 2025, Huang et al Nat Rev Gastro Hep 2023, ACG ACLF Guidelines 2022

- Mr. PS: 58-year-old Veteran with decompensated cirrhosis is on the floor.
- Stable HE on lactulose and rifaximin, ascites controlled on diuretics, and no variceal bleeding history. Last seen 1 month ago with MELD3.0 of 16.
- Seen in the hospital with mild confusion that is not responding to a higher lactulose dose by his wife. No signs of GI bleeding and SpO2>98% room air.

Labs	Outpatient 1M prior	On admission
WBC count	2.6	5.4
Creatinine	0.8	1.2
INR	1.5	1.7
Bilirubin	3.0	4.8
Sodium	139	134
Albumin	3.3	2.6
MELD3.0	16	23
Hematocrit	31	30
<u>Ammonia</u>	<u>Not done because you know better</u>	<u>48 (ULN 32) (done in the ER)</u>

Doubling of WBC count

New AKI: Creatinine ↑ >0.3mg/dl over baseline


Worsening of the liver disease overall

**With the confusion
=
Infection unless proven otherwise**

So what to do now to prevent ACLF development?

PACKAGE DEAL

- Diagnose and treat infections
- Avoid nosocomial infections
- Prevent HE worsening and aspiration
- Diagnose and treat AKI before ATN or HRS sets in
- Open lines of communication with families, transplant teams, and potential referral sites.



It is an infection unless
proven otherwise!

Cirrhosis-Associated Immune Dysfunction

Liver

Hepatic Reticuloendothelial System

Portosystemic shunt
Impairment of Kupffer cells
Sinusoidal capillarization

Protein Synthesis

↓ Complement component synthesis (C3, C4, CH50)
↓ Acute-phase proteins
↓ Soluble pattern recognition receptors
↓ Opsonization
↓ Protein C activity
↑ Chemotactic inhibitory activity

↓ Protein synthesis by hepatocytes

Loss of fenestrae on LSECs (capillarization)

Shunting

To systemic circulation

Kupffer-cell impairment

Circulation

Monocytes

↓ Antigen presentation capacity
↓ Adherence
↓ Production of proinflammatory cytokines (interleukin-1,6,18; TNF- α)

Macrophages

Persistent activation
↓ Phagocytosis
↓ Chemotaxis
↓ Fc-gamma receptor activity

Lymphocytes

Persistent activation
↓ CD27+ memory cells
↓ NK-cell function
↓ T cells (CD4+ and CD8+)
B-cell clonal proliferation
Altered immunoglobulin production

Circulation and Spleen

Neutrophils

Sequestration by the spleen
Persistent activation
↓ Phagocytosis
↓ Chemotaxis
↓ Migration
↓ Intracellular killing activity
↓ Life span

Other Related Factors

Malnutrition
Medications (glucocorticoids, other immune modulators)
Alcohol intake
Genetic predisposition (e.g., NOD2 or TLR2 variants)

Alterations in Gut Barrier


Changes to microbiome
↑ Pathobionts
↓ Synthesis of beneficial acids and metabolites

↓ Bile acids
↓ Antimicrobial peptides

↓ Production of mucosal barrier




↓ IgA secretion


Multiple levels where cirrhosis predisposes to infections



Clues that can indicate infections in cirrhosis

○ Usual signs of infection may be absent


- Altered mental status or hepatic encephalopathy 
- Acute kidney injury 
- Increase in WBC count may not be dramatic due to hypersplenism 




Important infections in cirrhosis:

- ✓ Spontaneous bacterial peritonitis
- ✓ UTI
- ✓ Respiratory tract infections
- ✓ Spontaneous bacteremia
- ✓ Skin and soft-tissue infections
- ✓ CDI

If infections are not dealt with soon →
dominoes start falling quickly!





ACG ACLF Guideline Recommendations: Infections

- Check for infection in hospitalized patients.
- In suspected infection, we suggest early antibiotics
- In patients not responding to antibiotic therapy, we recommend suspicion of a resistant organism or fungal infection
- In SBP albumin with antibiotics to prevent AKI and subsequent organ failures but not in other infections.


- ✓ Early broad-spectrum antibiotics following local sensitivities and after drawing cultures
 - ✓ Patient improving and sensitivities back? Narrow spectrum
 - ✓ Patient worsening? Broaden further, or add antifungal
- ✓ Avoid unnecessary albumin and be vigilant for nosocomial infections

Ascites, Refractory Ascites, AKI and HRS-AKI

A progression to avoid

Hint: teach house-staff how to do paracentesis!

Ascites dos and don'ts





- A timely tap to exclude SBP and ensure patients have relief is needed
- This will help avoid pneumonia, increase mobility, and improve nutrition
- Prevent PPCD by albumin infusion (6- 8 g/liter) during LVP of >5 L to avoid AKI
- LVP is the first- line treatment for RA but LT should be considered

Stages of AKI...very dynamic if ignored!

AKI Stage	Description
Stage 1	Increase of creatinine ≥ 0.3 mg/dL up to 2- fold of baseline
Stage 2	Increase in creatinine between 2- fold and 3- fold of baseline
Stage 3	Increase in creatinine >3 - fold of baseline or creatinine >4 mg/dL (353.6 $\mu\text{mol/L}$) with an acute increase ≥ 0.3 mg/dL (26.5 $\mu\text{mol/L}$) or initiation of RRT

Is all AKI HRS?....NO


- ✓ AKI + No response after diuretic withdrawal & albumin for 24 hours
- ✓ No shock, organic/structural renal disease or nephrotoxic drug use



Should everyone get terlipressin...not so fast!

Reconsider or is contraindicated

- ✓ Pre-Rx Creatinine >5mg/dl
- ✓ Pre-Rx SpO2 <90%
- ✓ ACLF-3 or higher
- ✓ Ischemic conditions
- ✓ Unclear diagnosis of HRS-AKI




Confusion

Is it HE? Or not....?

Overt HE: Important Points During the Acute Episode

What to avoid


- Ammonia levels instead of clinical exam
- Unnecessary head imaging
- Aspiration pneumonia
- Too much lactulose → dehydration & hypernatremia
- Delaying advanced care planning & transplant evaluation.





Expecting HE to improve
without fixing the
precipitant


= Sisyphean task!



What is unlikely to be HE? Important role of Alcohol


Unlikely cirrhosis-related HE

- Unclear history of cirrhosis
- Very rapid liver failure
- New-onset focal neurological deficits
- Seizures
- Recent/current alcohol or illicit drug use
- Other clinical situations where other conditions are more likely
- Normal ammonia levels in a comatose patient*



Variceal bleeding...going but not totally gone!


Patients are also prone to acid peptic
diseases



- **Presentation:** Melena, coffee grounds, or hematemesis
- **Priorities**
 - Airway support, intubate if needed.
 - Hemodynamic support with fluids
 - ICU or stepdown monitoring
- **Differentials**
 - Acid peptic disease
 - Mallory Weiss tears
- **Pre-endoscopy medications**
 - IV PPI
 - IV somatostatin analogues
 - IV ceftriaxone
 - IV erythromycin if high volume/clots suspected
- **Transfuse cautiously till Hgb 7-9 g/dl**




Esophageal variceal bleeding



- What if bleeding does not stop?
 - Balloon tamponade as a bridge to urgent TIPS
- TIPS in esophageal variceal bleeding?
 - Salvage: Initial treatment not working
 - Pre-emptive: initial treatment worked but still have high-risk stigmata for re-bleeding
 - Rescue: Early re-bleeding within 2-5 days

Gastro-fundal variceal bleeding

- Local expertise is key
- Comfort with cyanoacrylate injection / coil?
- Availability of TIPS/RTO
 - TIPS>>RTO when
 - Liver function maintained
 - Large varices & ascites
 - PVT
 - RTO>>TIPS when
 - Prior HE
 - Poor liver function



Important issues, caveats and variations

Using clinical variables on day of admission: Machine learning >>> traditional statistics for mortality prediction

Global variations in cirrhosis care →
Suboptimal mortality prediction with traditional
statistics

Could Machine Learning Approaches Help?



Global derivation
cohort with 7,239
cirrhosis inpatients



US Veterans
validation

VA-Corporate Data
Warehouse with 28,670
cirrhosis inpatients

Random Forest Model = Highest AUC &
calibration >> Logistic regression, XG Boost,
LASSO, & MELD-Na/MELD3.0

- ✓ Results similar regardless of country income, alcohol, HE, and infections.
- ✓ Externally validated in VA cohort

**Globally derived & externally validated
random forest model is best in
predicting inpatient cirrhosis mortality**

Silvey et al 2025 CLEARED

Gastroenterology

MODEL freely available: https://silveys.shinyapps.io/app_cleared/

Issue with diagnosis of cirrhosis in inpatients

Everyone's a suspect: MISSING IT

- Background prevalence is high
- 10-13% of patients with dementia had undiagnosed cirrhosis and ?HE
- Look for low platelet count and albumin and high FIB-4 in patients seen for other conditions
- Higher risk in
 - Diabetes
 - Other components of metabolic syndrome
 - Alcohol use disorder

Assumed: Acute liver failure vs ACLF

	Acute Liver Failure	ACLF
Background Liver Disease severity	No chronic liver disease	Chronic Liver disease or cirrhosis
Insults	Viral hepatitis, Medications,	Viral infection or flare, Infections, DILI, Alcohol, Surgery, TIPS
Hepatic failure required	Yes	Yes
Extra-hepatic Organ failure needed	No, even milder grades of HE are considered diagnostic	Yes
Course	High rate of death with infections and cerebral edema	High rate of death due to hepatic and extra-hepatic organ failure
Transplant suitability	Status 1 (UNOS US-based)	Priority based on MELD-Na score.

Things to remember at the time of discharge, otherwise, patients will be readmitted

- **General**: Ensure follow-up appointment with GI/Hepatology
- **HE**: ensure medication(s) in hand, counsel patient and family, ensure underlying factor(s) behind episodes are addressed.
- **Variceal bleeding**: Complete Abx prophylaxis, Stop PPI, start carvedilol & schedule f/u EGD
- **Ascites/SBP/AKI**: Optimal diuretics, consideration for TIPS or taps as needed, re-evaluate prophylaxis
- **Involve other team members**: Substance abuse, nutrition, physical therapy, IR, PMD, liver transplant team

What happened to Mr. PS?

- **Responsive team**

- ✓ Rapid paracentesis found SBP, and blood/ascites cultures sent

- **Team that needs more education**

- × IR busy, paracentesis took >24 hours

A few hours and ensuring awareness can make all the difference!

- ✓ day 2 and was discharged day 4 with outpatient antibiotics sensitive to the cultures.
- ✓ Transplant work-up initiated.

AKI and hypoxia.

- × Broad spectrum antibiotics started but patient needed intubation.
- × Family meeting called, dialysis not initiated, and patient passed away.

Take home points

- Cirrhosis is often hidden in plain sight...do not miss it!
- Rapid, flexible, and team-based response is needed to prevent ACLF
- Early need for LT or palliative care input
- Complications come as an unfortunate “Package Deal”
- Everything is due to an infection unless proven otherwise
- It is better to de-escalate antibiotics than wait to escalate.
- Not all confusion is HE and not all high creatinine is HRS-AKI.
- UGI bleeding is not always variceal so change medicines accordingly
- Antibiotic resistance is a pandemic, and cirrhosis is the tip of the spear
- Our responsibility does not end at discharge
- Cirrhosis care is team-based, where communication and time are key

Acknowledgements

NACSELD PIs/team

- Jacqueline O’Leary, MD
- Florence Wong, MD
- K Rajender Reddy, MD
- Patrick S Kamath, MD
- Guadalupe Garcia-Tsao, MD
- Jennifer Lai, MD
- Puneeta Tandon, MD
- Hugo Vargas, MD
- Scott Biggins, MD
- Paul Thuluvath, MD
- Ram Subramanian, MD
- Leroy R Thacker, PhD
- Brian J Bush, MS

VCU/VA Gastroenterology and Hepatology

- Arun J Sanyal, MD
- Douglas M Heuman, MD
- William M Pandak, MD
- Richard K Sterling, MD
- R Todd Stravitz, MD
- Velimir Luketic, MD
- Puneet Puri, MD
- Michael Fuchs, MD
- Mohammed S Siddiqui, MD
- Scott C Matherly, MD
- Brian C Davis, MD
- Hannah Lee, MD
- Joel Wedd, MD
- HoChong Gilles, NP
- Abhishek Shenoy, MD

VCU/VA coordination

- Andrew Fagan, BS
- Mary Leslie Gallagher, NP
- Amy Bartels, RN
- Haley Obolewicz, RN
- Travis Mousel, RN

University of Southern Denmark

Mette Lauridsen, MD
Lea Longkaer, RN

*Funding: VA Merit Review I0CX001076,
I01CX002472, RO1AA298398,*